Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Raw Materials (2022 - 2025)

Historic Raw Materials for Gyre Therapeutics (GYRE) over the last 4 years, with Q3 2025 value amounting to $1.1 million.

  • Gyre Therapeutics' Raw Materials rose 577.48% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 577.48%. This contributed to the annual value of $794000.0 for FY2024, which is 1360.17% down from last year.
  • Gyre Therapeutics' Raw Materials amounted to $1.1 million in Q3 2025, which was up 577.48% from $1.2 million recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Raw Materials high stood at $1.2 million for Q2 2025, and its period low was $724000.0 during Q1 2024.
  • Over the past 4 years, Gyre Therapeutics' median Raw Materials value was $1.1 million (recorded in 2022), while the average stood at $1.0 million.
  • Its Raw Materials has fluctuated over the past 5 years, first tumbled by 1360.17% in 2024, then surged by 6146.41% in 2025.
  • Over the past 4 years, Gyre Therapeutics' Raw Materials (Quarter) stood at $1.1 million in 2022, then decreased by 12.97% to $919000.0 in 2023, then fell by 13.6% to $794000.0 in 2024, then surged by 38.41% to $1.1 million in 2025.
  • Its Raw Materials was $1.1 million in Q3 2025, compared to $1.2 million in Q2 2025 and $1.2 million in Q1 2025.